Behandling med Tracleer var forbundet med en signifikant reduktion i forekomsten af klinisk forværring i sammenligning med placebo ved 28 uger (henholdsvis 10, 7% imod 37, 1%; p = 0, 0015).
Treatment with Tracleer was associated with a significant reduction in the rate of clinical worsening compared with placebo at 28 weeks (10.7% vs 37.1%, respectively; p = 0.0015).